CDK4 and breast cancer: For these reasons, the focus of this review is to discuss the role of FGFR alterations during the development of resistance to CDK4/6 inhibitors and how targeting the FGFR pathway could be utilized therapeutically to overcome CDK4/6 inhibitor therapy resistance in BC will be further debated.